drugset / Trial / NCT04289220
Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia
NaSingle-groupOpen-labelTreatment
Summary
Our previous study demonstrated that anti-CD19 chimeric antigen receptor in piggyBac transposon-engineered T cells have strong tumor-killing activity in vitro and therapeutic effects in cell line-derived xenograft models, and no obvious side effects such as neurotoxicity and cytokine storm occurred. Therefore, we want to evaluate the safety and clinical effect of anti-CD19 CAR-T cells in clinical trials.
Timeline
- Start
- 2020-03-15
- Primary completion
- 2023-03-15
- Completion
- 2023-09-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-CD19 CAR-T cells | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | anti-CD19 CAR-T cells | Cell therapy | 2.5e+06 cells/kg | Intravenous |